[go: up one dir, main page]

BRPI1012892B8 - compostos de fórmula (i), como tal, composição farmacêutica que os compreende e seu uso no tratamento de hgps, progeria, desordem de charcot-marie-tooth, síndrome de werner, diabetes, osteoporose e envelhecimento da pele - Google Patents

compostos de fórmula (i), como tal, composição farmacêutica que os compreende e seu uso no tratamento de hgps, progeria, desordem de charcot-marie-tooth, síndrome de werner, diabetes, osteoporose e envelhecimento da pele

Info

Publication number
BRPI1012892B8
BRPI1012892B8 BRPI1012892A BRPI1012892A BRPI1012892B8 BR PI1012892 B8 BRPI1012892 B8 BR PI1012892B8 BR PI1012892 A BRPI1012892 A BR PI1012892A BR PI1012892 A BRPI1012892 A BR PI1012892A BR PI1012892 B8 BRPI1012892 B8 BR PI1012892B8
Authority
BR
Brazil
Prior art keywords
group
pharmaceutical composition
hgps
progeria
charcot
Prior art date
Application number
BRPI1012892A
Other languages
English (en)
Inventor
Scherrer Didier
Mahuteau Florence
Tazi Jamal
Santo Julien
Najman Romain
Original Assignee
Abivax
Centre Nat Rech Scient
Inst Curie
Soc Splicos
Univ Montpellier
Univ Montpellier 2
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20090305540 external-priority patent/EP2266972A1/en
Priority claimed from EP09162630A external-priority patent/EP2261214A1/en
Application filed by Abivax, Centre Nat Rech Scient, Inst Curie, Soc Splicos, Univ Montpellier, Univ Montpellier 2 filed Critical Abivax
Publication of BRPI1012892A2 publication Critical patent/BRPI1012892A2/pt
Publication of BRPI1012892B1 publication Critical patent/BRPI1012892B1/pt
Publication of BRPI1012892B8 publication Critical patent/BRPI1012892B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

composto, e, composição farmacêutica a presente invenção diz respeito a composto (i) (i) em que: significa um grupo piridazina, pirimidina ou pirazina, r independentemente representam um átomo de hidrogênio, um átomo de halogênio ou um grupo escolhido entre um grupo -cn, um grupo hidroxila, um grupo -coor1, um grupo fluoralquila (c1-c3), um grupo fluoralcóxi (c1-c3), um grupo -no2, um grupo -nr1r2, um grupo alcóxi (c1-c4), um grupo fenóxi e um grupo alquila (c1-c3), o dito alquila sendo opcionalmente mono-substituído por um grupo hidroxila, n é 1,2 ou 3, n' é 1 ou 2, r' é um átomo de hidrogênio, um átomo de halogênio ou um grupo escolhido entre um grupo alquila (c1-c3), um grupo hidroxila, um grupo -coor1, um grupo -no2, um grupo -nr1r2, um morfolinila ou um grupo morfolino, um grupo n-metilpiperazinila, um grupo fluoralquila (c1-c3), um grupo alcóxi (c1-c4) e um grupo -cn, z é n ou c, y é n ou c. x é n ou c, w é n ou c, t é n ou c, u é n ou c, para uso como um agente para prevenir, inibir ou tratar condições patológicas ou não patológicas ligadas ao envelhecimento prematuro.alguns dos ditos composto são novos e também formam parte da invenção.
BRPI1012892A 2009-06-12 2010-06-14 compostos de fórmula (i), como tal, composição farmacêutica que os compreende e seu uso no tratamento de hgps, progeria, desordem de charcot-marie-tooth, síndrome de werner, diabetes, osteoporose e envelhecimento da pele BRPI1012892B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09162630.9 2009-06-12
EP20090305540 EP2266972A1 (en) 2009-06-12 2009-06-12 New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies
EP09162630A EP2261214A1 (en) 2009-06-12 2009-06-12 Compounds useful to treat premature aging and in particular progeria
EP09305540.8 2009-06-12
PCT/IB2010/052652 WO2010143170A2 (en) 2009-06-12 2010-06-14 Compounds useful for treating premature aging and in particular progeria

Publications (3)

Publication Number Publication Date
BRPI1012892A2 BRPI1012892A2 (pt) 2018-03-13
BRPI1012892B1 BRPI1012892B1 (pt) 2020-10-27
BRPI1012892B8 true BRPI1012892B8 (pt) 2021-05-25

Family

ID=43309298

Family Applications (5)

Application Number Title Priority Date Filing Date
BR122019013686-6A BR122019013686B1 (pt) 2009-06-12 2010-06-14 Composto de fórmula (i), composto de fórmula (iq) e composição farmacêutica
BRPI1010772A BRPI1010772B8 (pt) 2009-06-12 2010-06-14 compostos de quinolina, suas composições farmacêuticas e seus usos para tratar aids
BRPI1010768A BRPI1010768C8 (pt) 2009-06-12 2010-06-14 composto de fórmula (i)
BRPI1012892A BRPI1012892B8 (pt) 2009-06-12 2010-06-14 compostos de fórmula (i), como tal, composição farmacêutica que os compreende e seu uso no tratamento de hgps, progeria, desordem de charcot-marie-tooth, síndrome de werner, diabetes, osteoporose e envelhecimento da pele
BR122019013687A BR122019013687B1 (pt) 2009-06-12 2010-06-14 composto de fórmula (i)

Family Applications Before (3)

Application Number Title Priority Date Filing Date
BR122019013686-6A BR122019013686B1 (pt) 2009-06-12 2010-06-14 Composto de fórmula (i), composto de fórmula (iq) e composição farmacêutica
BRPI1010772A BRPI1010772B8 (pt) 2009-06-12 2010-06-14 compostos de quinolina, suas composições farmacêuticas e seus usos para tratar aids
BRPI1010768A BRPI1010768C8 (pt) 2009-06-12 2010-06-14 composto de fórmula (i)

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122019013687A BR122019013687B1 (pt) 2009-06-12 2010-06-14 composto de fórmula (i)

Country Status (24)

Country Link
US (7) US20120329796A1 (pt)
EP (6) EP2440547B1 (pt)
JP (8) JP5826745B2 (pt)
KR (14) KR101982463B1 (pt)
CN (13) CN104844570B (pt)
AU (3) AU2010258214B2 (pt)
BR (5) BR122019013686B1 (pt)
CA (5) CA2764024C (pt)
CU (4) CU24245B1 (pt)
DK (4) DK3517534T3 (pt)
ES (4) ES2985082T3 (pt)
FI (3) FI2440546T3 (pt)
HK (8) HK1173153A1 (pt)
HR (3) HRP20230248T1 (pt)
HU (2) HUE061262T2 (pt)
LT (1) LT2440547T (pt)
MX (10) MX353776B (pt)
PL (4) PL3517534T3 (pt)
PT (4) PT2440547T (pt)
RU (1) RU2567752C2 (pt)
SI (1) SI2440547T1 (pt)
TR (1) TR201910781T4 (pt)
WO (3) WO2010143168A2 (pt)
ZA (2) ZA201109031B (pt)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
ES2985082T3 (es) 2009-06-12 2024-11-04 Abivax Compuestos útiles para tratar el cáncer
MX2019008390A (es) * 2009-06-12 2019-09-09 Abivax Compuestos utiles para tratar cancer.
WO2011028947A2 (en) 2009-09-03 2011-03-10 Bioenergenix Heterocyclic compounds for the inhibition of pask
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
EP2465502A1 (en) * 2010-12-15 2012-06-20 Société Splicos Compounds useful for treating AIDS
JP5980812B2 (ja) 2011-01-05 2016-08-31 バイオエナジェニックス Ｐａｓｋの阻害のための複素環化合物
US8916561B2 (en) 2011-03-02 2014-12-23 Bioenergenix, Llc Substituted quinoxaline compounds for the inhibition of PASK
EP2681207B1 (en) 2011-03-02 2016-12-28 Bioenergenix Heterocyclic compounds for the inhibition of pask
GB201118652D0 (en) * 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
FR2987627B1 (fr) 2012-03-05 2016-03-18 Splicos Utilisation de rbm39 comme biomarqueur
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
EP2863920B1 (en) 2012-06-20 2023-03-22 Eutropics Pharmaceuticals, Inc. Quinoline derivatives for use in the tratment of breast cancer
TW201410657A (zh) 2012-08-02 2014-03-16 Endo Pharmaceuticals Inc 經取代胺基－嘧啶衍生物
JP6193374B2 (ja) 2012-08-13 2017-09-06 武田薬品工業株式会社 Ｇｐｒ６モジュレーターとしてのキノキサリン誘導体
JP2014237624A (ja) * 2012-10-23 2014-12-18 日本曹達株式会社 ピリジン化合物またはその塩、有害生物防除剤、殺虫剤または殺ダニ剤、および外部寄生虫防除剤
WO2014081953A1 (en) 2012-11-21 2014-05-30 Richard David J Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
GB201301571D0 (en) * 2012-11-27 2013-03-13 Fundanci N Pedro Barri De La Maza Product and use
US20140194465A1 (en) * 2013-01-04 2014-07-10 Novarx Corporation Compositions for treatment of cancer
EP2757161A1 (en) * 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
BR112016000127B1 (pt) * 2013-07-05 2022-02-15 Abivax Compostos bicíclicos úteis para tratar doenças causadas por retrovírus
JPWO2015005491A1 (ja) * 2013-07-12 2017-03-02 国立大学法人京都大学 疾病の発症又は進行の一因となる異常スプライシングを抑制できる物質のスクリーニング方法
US10732182B2 (en) 2013-08-01 2020-08-04 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
WO2015066305A1 (en) 2013-10-30 2015-05-07 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
JO3466B1 (ar) 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
JP6526034B2 (ja) 2014-02-14 2019-06-05 武田薬品工業株式会社 Ｇｐｒ６のピリドピラジンモジュレーター
US10736900B2 (en) 2014-03-26 2020-08-11 Astex Therapeutics Ltd Combinations of an FGFR inhibitor and an IGF1R inhibitor
MA39784B1 (fr) 2014-03-26 2021-03-31 Astex Therapeutics Ltd Combinaisons des inhibiteurs du fgfr et du cmet destinées au traitement du cancer
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
EP2975034A1 (en) 2014-07-17 2016-01-20 Abivax A quinoline derivative for the treatment of inflammatory diseases and AIDS
MX381238B (es) 2015-01-30 2025-03-12 Centre National De La Recherche Scient Cnrs Isoformas delta133p53beta y delta133p53gamma son biomarcadores de células madre cancerosas.
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
EP3059591A1 (en) * 2015-02-23 2016-08-24 Abivax Methods for screening compounds for treating or preventing a viral infection or a virus-related condition
EP3059236A1 (en) 2015-02-23 2016-08-24 Abivax A new quinoline derivative for use in the treatment and prevention of viral infections
EP3058940A1 (en) * 2015-02-23 2016-08-24 Abivax Quinoline derivatives for use in the treatment or prevention of viral infection
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
SI3353164T1 (sl) 2015-09-23 2022-02-28 Janssen Pharmaceutica, N.V. Bi-heteroaril substituiran 1,4-benzodiazepini in njihove uporabe za zdravljenje raka
EP3353177B1 (en) 2015-09-23 2020-06-03 Janssen Pharmaceutica NV Tricyclic heterocycles for the treatment of cancer
AU2016371466B2 (en) 2015-12-17 2020-04-09 Alonbio Ltd Small Molecules for Inhibiting Chemokine Activity and/or Cancer Cells Growth
US10646465B2 (en) 2015-12-17 2020-05-12 Biokine Therapeutics Ltd. Small molecules against cancer
JP6966456B2 (ja) * 2016-02-03 2021-11-17 ヤンセン ファーマシューティカ エヌ．ベー． タウｐｅｔ画像化リガンド
WO2017158201A1 (en) * 2016-03-18 2017-09-21 Ratiopharm Gmbh Process for preparing quinolin-2-yl-phenylamine derivatives and their salts
ES2846833T3 (es) 2016-07-18 2021-07-29 Janssen Pharmaceutica Nv Ligandos de obtención de imágenes de tau por PET
CN106496061B (zh) * 2016-10-20 2018-06-05 湘潭大学 一种萃取分离酰化反应液中乙酰精胺的方法
AR112027A1 (es) * 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
CN110996983A (zh) * 2017-06-26 2020-04-10 巴斯德研究所 清除hiv储库并降低病毒载量的治疗
WO2019045655A1 (en) 2017-08-29 2019-03-07 Chulabhorn Foundation DERIVATIVES AND COMPOSITION OF QUINOLINE AND NAPHTHYRIDINE
US20200039989A1 (en) * 2018-03-01 2020-02-06 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of dyrk/clk and uses thereof
WO2019186277A1 (en) 2018-03-28 2019-10-03 Institut Pasteur Ultrasensitive hiv-1 p24 detection assay
EP3594206A1 (en) 2018-07-09 2020-01-15 Abivax Phenyl-n-quinoline derivatives for treating a rna virus infection
EP3594205A1 (en) * 2018-07-09 2020-01-15 Abivax Phenyl-n-aryl derivatives for treating a rna virus infection
EP3669873A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases
WO2020128033A1 (en) 2018-12-20 2020-06-25 Institut Pasteur Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells
EP3669874A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use in the treatment or prevention of cancer
EP4524131A1 (en) 2019-05-15 2025-03-19 AlonBio Ltd. Small molecules for treating cancer, inhabiting chemokine activity and/or inducing cell death
WO2021152129A1 (en) 2020-01-31 2021-08-05 Abivax Amorphous solid dispersion of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine
EP3858336A1 (en) 2020-01-31 2021-08-04 Abivax Amorphous solid dispersion of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine
EP3858815A1 (en) 2020-01-31 2021-08-04 Abivax Co-crystals and salts of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine
IL296522A (en) 2020-03-20 2022-11-01 Abivax Compounds for treating or preventing coronaviridae infection and methods and uses for assessing the occurrence of coronaviridae infection
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
BR112023000047A2 (pt) 2020-07-02 2023-03-14 Incyte Corp Compostos de ureia tricíclicos como inibidores da v617f da jak2
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
TW202302589A (zh) 2021-02-25 2023-01-16 美商英塞特公司 作為ｊａｋ２ ｖ６１７ｆ抑制劑之螺環內醯胺
EP4063351A1 (en) 2021-03-26 2022-09-28 Abivax Preparation method of quinoline derivative compounds
CN117222639A (zh) 2021-05-27 2023-12-12 江苏恒瑞医药股份有限公司 喹啉胺类化合物、其制备方法及其在医药上的应用
KR20230072900A (ko) 2021-11-18 2023-05-25 동우 화인켐 주식회사 마이크로 led 구조체 및 이의 제조방법
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator
EP4215196A1 (en) 2022-01-24 2023-07-26 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor
WO2023138657A1 (zh) * 2022-01-24 2023-07-27 江苏恒瑞医药股份有限公司 喹啉胺类化合物、其制备方法及其在医药上的应用
EP4493558A1 (en) 2022-03-17 2025-01-22 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2025027388A1 (en) 2023-08-01 2025-02-06 Abivax Obefazimod for treatment of ulcerative colitis
WO2025045123A1 (zh) * 2023-08-30 2025-03-06 江苏正大丰海制药有限公司 用于调节微小rna-124活性的化合物

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR400973A (fr) 1909-03-19 1909-08-13 Jean Victor Massillon Nouveau sertisseur à main pour la fabrication des cartouches
GB585362A (en) 1944-08-31 1947-02-05 Francis Henry Swinden Curd New heterocyclic compounds
BE486034A (pt) 1947-11-28
DE958647C (de) 1952-12-28 1957-02-21 Hoechst Ag Verfahren zur Herstellung von 7-Amino-2-oxy-4-methyl-chinolinen
FR2387229A1 (fr) 1977-04-13 1978-11-10 Anvar Dipyrido (4,3-b) (3,4-f) indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant
FR2436786A1 (fr) 1978-09-21 1980-04-18 Anvar Nouveaux derives des pyrido (4,3-b) carbazoles (ellipticines), substitues en position 1 par une chaine polyaminee, leur obtention et leur application a titre de medicaments
FR2627493B1 (fr) * 1988-02-23 1991-10-31 Sanofi Sa Procede de preparation de derives d'isoquinoleine
FR2645861A1 (fr) * 1989-04-17 1990-10-19 Inst Nat Sante Rech Med Utilisation de dipyrido (4,3-b) (3,4-f) indoles pour la preparation de medicaments utiles pour le traitement du sida
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
ATE260099T1 (de) 1999-04-05 2004-03-15 Hope City Neue hemmern von fortgeschrittenen glykosilierung-endprodukten
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
DE10013318A1 (de) * 2000-03-17 2001-09-20 Merck Patent Gmbh Formulierung enthaltend Chinoxalinderivate
CA2435847A1 (en) 2001-01-22 2002-09-26 Memory Pharmaceuticals Corporation Aniline derivatives useful as phosphodiesterase 4 inhibitors
ES2355472T3 (es) 2002-05-22 2011-03-28 Amgen Inc. Derivados de aminopirimidina para su uso como ligandos del receptor vaniloide para el tratamiento del dolor.
AU2002950217A0 (en) * 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
WO2004009552A1 (en) * 2002-07-19 2004-01-29 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
FR2849474B3 (fr) 2002-12-27 2004-12-03 Olivier Jean Noel Juin Installation de transformation de l'energie cinetique d'un fluide en energie electrique
WO2004078731A1 (fr) 2003-03-06 2004-09-16 'chemical Diversity Research Institute', Ltd. Acides quinoline-carboxyliques et leurs derives et bibliotheque focalisee
JP2006519846A (ja) * 2003-03-10 2006-08-31 シェーリング　コーポレイション 複素環式キナーゼインヒビター：使用および合成の方法
FR2859474B1 (fr) 2003-09-04 2006-01-13 Centre Nat Rech Scient Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage
FR2859475A1 (fr) 2003-09-04 2005-03-11 Centre Nat Rech Scient Utilisation de composes derives d'ellipticine et d'aza-ellipticine pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage
AU2004281154A1 (en) * 2003-10-16 2005-04-28 Novartis Vaccines And Diagnostics, Inc. 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of Raf kinase for treatment of cancer
JP4842137B2 (ja) * 2003-11-19 2011-12-21 アレイ バイオファーマ、インコーポレイテッド Ｍｅｋのヘテロ環系阻害剤及びその使用方法
WO2006051311A1 (en) * 2004-11-12 2006-05-18 Galapagos Nv Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
EP1853265B1 (en) 2005-01-28 2016-01-27 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Farnesyltransferase inhibitors for use in the treatment of laminopathies, cellular aging and atherosclerosis
EP1897914A4 (en) * 2005-06-29 2008-07-02 Adeka Corp RESIN ADDITIVE COMPOSITION AND RESIN COMPOSITION
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
WO2008008234A1 (en) * 2006-07-07 2008-01-17 Targegen, Inc. 2-amino-5-substituted pyrimidine inhibitors
EP2121620B1 (en) * 2007-01-19 2015-06-17 Ardea Biosciences, Inc. Inhibitors of mek
FR2912745A1 (fr) 2007-02-19 2008-08-22 Centre Nat Rech Scient Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant
US20100249184A1 (en) * 2007-03-16 2010-09-30 Mount Sinai School Of Medicine Induction and/or maintenance of tumor dormancy by disruption of urokinase plasminogen activator receptor-integrin interaction
TWI371445B (en) 2007-05-17 2012-09-01 Lg Chemical Ltd New anthracene derivatives and organic electronic device using the same
UY31272A1 (es) * 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
CA2695456A1 (en) 2007-08-15 2009-02-19 Robert Dunn 3' substituted compounds having 5-ht6 receptor affinity
WO2009029617A1 (en) * 2007-08-27 2009-03-05 Kalypsys, Inc. Diarylamine-substituted quinolones useful as inducible nitric oxide synthase inhibitors
KR100974562B1 (ko) * 2007-12-31 2010-08-06 다우어드밴스드디스플레이머티리얼 유한회사 신규한 유기 발광 화합물 및 이를 발광재료로서 채용하고있는 유기 발광 소자
FR2926297B1 (fr) 2008-01-10 2013-03-08 Centre Nat Rech Scient Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage.
US20110311475A1 (en) * 2009-01-05 2011-12-22 Stephan Borte Means and method for the treatment of antibody deficiency diseases based on il-21 and il-21 variants
JP5828151B6 (ja) * 2009-01-06 2018-09-19 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル アテローム性動脈硬化の処置のためのｂ細胞枯渇剤
EP2373611A2 (en) * 2009-01-06 2011-10-12 DSM IP Assets B.V. Process for resveratrol intermediate
MX2019008390A (es) * 2009-06-12 2019-09-09 Abivax Compuestos utiles para tratar cancer.
EP2266972A1 (en) 2009-06-12 2010-12-29 Splicos New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies
ES2985082T3 (es) * 2009-06-12 2024-11-04 Abivax Compuestos útiles para tratar el cáncer
WO2010151755A2 (en) 2009-06-25 2010-12-29 The Brigham And Women's Hospital, Inc. TREATMENT OF INFLAMMATORY DISEASES USING miR-124
EP2465502A1 (en) 2010-12-15 2012-06-20 Société Splicos Compounds useful for treating AIDS
EP2903611A4 (en) 2012-10-04 2016-11-16 Oyagen Inc SMALL MOLECULES AS ANTI-HIV AGENTS FOR INTERRUPTING THE VIF SELF-ASSOCIATION AND METHOD FOR USE THEREOF
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
JP2015120566A (ja) * 2013-12-20 2015-07-02 ニチユ三菱フォークリフト株式会社 荷役車両

Also Published As

Publication number Publication date
CN102574835B (zh) 2014-04-16
KR20190018570A (ko) 2019-02-22
WO2010143168A3 (en) 2011-06-09
EP2440545A2 (en) 2012-04-18
CN104945378A (zh) 2015-09-30
CN102596935A (zh) 2012-07-18
FI2440546T3 (fi) 2023-03-30
CN106928205B (zh) 2019-09-24
KR20180100737A (ko) 2018-09-11
CA2965791C (en) 2020-06-09
MX364280B (es) 2019-04-22
US20120329796A1 (en) 2012-12-27
KR101973348B1 (ko) 2019-04-26
AU2010258214A1 (en) 2012-01-19
KR101863021B1 (ko) 2018-05-30
DK2440547T3 (da) 2023-02-20
AU2010258294B2 (en) 2015-07-30
BRPI1010768C8 (pt) 2020-04-07
PL3517534T3 (pl) 2024-06-24
CN104945378B (zh) 2018-11-20
EP2440546A2 (en) 2012-04-18
WO2010143170A3 (en) 2011-08-11
ZA201109032B (en) 2013-02-27
CN102625804B (zh) 2015-04-08
BR122019013686B1 (pt) 2020-03-17
HRP20240582T1 (hr) 2024-07-19
HK1212702A1 (zh) 2016-06-17
US9108919B2 (en) 2015-08-18
EP3517534B1 (en) 2024-02-28
EP2440547B1 (en) 2022-11-30
SI2440547T1 (sl) 2023-05-31
PT2440547T (pt) 2023-02-17
JP2015187150A (ja) 2015-10-29
KR102016889B1 (ko) 2019-08-30
PT3517534T (pt) 2024-05-17
CN106928194A (zh) 2017-07-07
JP2015187151A (ja) 2015-10-29
JP2012529494A (ja) 2012-11-22
KR20170124646A (ko) 2017-11-10
HK1173726A1 (zh) 2013-05-24
PT2440546T (pt) 2023-03-27
KR20180101727A (ko) 2018-09-13
LT2440547T (lt) 2023-03-10
EP3517534A1 (en) 2019-07-31
CN104945379B (zh) 2018-11-30
BR122019013687B1 (pt) 2020-04-14
CN102625804A (zh) 2012-08-01
MX340095B (es) 2016-06-27
RU2567752C2 (ru) 2015-11-10
US9637475B2 (en) 2017-05-02
KR102016893B1 (ko) 2019-08-30
KR101769616B1 (ko) 2017-08-18
RU2011149572A (ru) 2013-07-20
WO2010143168A2 (en) 2010-12-16
KR101982461B1 (ko) 2019-05-24
JP2012529495A (ja) 2012-11-22
KR102016891B1 (ko) 2019-08-30
EP3521283A1 (en) 2019-08-07
MX364989B (es) 2019-05-17
JP2015187152A (ja) 2015-10-29
JP2020045342A (ja) 2020-03-26
HK1212990A1 (zh) 2016-06-24
KR20170092720A (ko) 2017-08-11
CU24245B1 (es) 2017-02-02
JP2012529493A (ja) 2012-11-22
AU2010258295A1 (en) 2012-01-19
CN103948594A (zh) 2014-07-30
CA2764027C (en) 2020-11-03
AU2010258295B2 (en) 2015-09-03
JP2015155453A (ja) 2015-08-27
WO2010143169A3 (en) 2011-11-10
MX2011013122A (es) 2012-07-23
CU24461B1 (es) 2020-01-03
EP4198022A1 (en) 2023-06-21
KR101897221B1 (ko) 2018-09-10
BRPI1010772B8 (pt) 2021-05-25
CN106928194B (zh) 2019-11-12
CA2764024C (en) 2017-12-05
JP5905385B2 (ja) 2016-04-20
CA2764026A1 (en) 2010-12-16
PL2440545T3 (pl) 2019-11-29
KR102016890B1 (ko) 2019-08-30
BRPI1010768B1 (pt) 2019-10-22
JP6041671B2 (ja) 2016-12-14
KR20190018569A (ko) 2019-02-22
US9145367B2 (en) 2015-09-29
FI3517534T3 (fi) 2024-05-16
KR102016892B1 (ko) 2019-08-30
CN104844570B (zh) 2018-11-02
MX364279B (es) 2019-04-22
KR20180100736A (ko) 2018-09-11
KR20190018571A (ko) 2019-02-22
US20150307478A1 (en) 2015-10-29
US20120277230A1 (en) 2012-11-01
HK1173447A1 (zh) 2013-05-16
CU20110230A7 (es) 2012-04-15
CN113004249A (zh) 2021-06-22
CN104844510A (zh) 2015-08-19
MX367601B (es) 2019-08-28
JP6158251B2 (ja) 2017-07-05
BRPI1010772A2 (pt) 2016-11-01
MX338823B (es) 2016-05-03
JP6158250B2 (ja) 2017-07-05
WO2010143169A2 (en) 2010-12-16
RU2011149571A (ru) 2013-07-20
EP3521283B1 (en) 2024-02-28
US20140288120A1 (en) 2014-09-25
CA2764024A1 (en) 2010-12-16
FI2440547T3 (fi) 2023-03-14
JP7042245B2 (ja) 2022-03-25
HRP20230143T1 (hr) 2023-03-31
US20120283265A1 (en) 2012-11-08
CN103948594B (zh) 2016-10-26
CN102574835A (zh) 2012-07-11
HK1200363A1 (en) 2015-08-07
HUE061262T2 (hu) 2023-05-28
EP2440546B1 (en) 2022-12-28
KR101789275B1 (ko) 2017-11-20
DK3517534T3 (da) 2024-05-27
MX373120B (es) 2025-03-05
US20140080831A1 (en) 2014-03-20
KR101982463B1 (ko) 2019-05-24
KR20120051643A (ko) 2012-05-22
ES2940885T3 (es) 2023-05-12
JP5826745B2 (ja) 2015-12-02
CN102596935B (zh) 2015-02-18
ES2938532T3 (es) 2023-04-12
US10017498B2 (en) 2018-07-10
PL2440546T3 (pl) 2023-07-10
MX2011013120A (es) 2012-07-23
HK1213247A1 (zh) 2016-06-30
CN109776496B (zh) 2021-09-28
BRPI1010768A8 (pt) 2019-07-30
BRPI1010768B8 (pt) 2020-03-10
TR201910781T4 (tr) 2019-08-21
CN104844510B (zh) 2019-04-23
BRPI1010768A2 (pt) 2016-11-01
CN104945379A (zh) 2015-09-30
BRPI1012892A2 (pt) 2018-03-13
EP2440545B1 (en) 2019-04-24
HK1173153A1 (en) 2013-05-10
KR20190018567A (ko) 2019-02-22
BRPI1012892B1 (pt) 2020-10-27
ES2985082T3 (es) 2024-11-04
HUE045548T2 (hu) 2019-12-30
CN106905232A (zh) 2017-06-30
KR20180100735A (ko) 2018-09-11
CN106928205A (zh) 2017-07-07
KR20120054585A (ko) 2012-05-30
CU20110228A7 (es) 2012-04-15
CU24124B1 (es) 2015-08-27
MX353776B (es) 2018-01-29
AU2010258294A1 (en) 2012-01-19
MX359575B (es) 2018-10-03
PT2440545T (pt) 2019-07-19
US20150299129A1 (en) 2015-10-22
ZA201109031B (en) 2013-02-27
CN109776496A (zh) 2019-05-21
CA3070823A1 (en) 2010-12-16
US9908869B2 (en) 2018-03-06
HK1213246A1 (zh) 2016-06-30
DK2440545T3 (da) 2019-07-22
CN104844570A (zh) 2015-08-19
CA2965791A1 (en) 2010-12-16
MX364282B (es) 2019-04-22
HRP20230248T1 (hr) 2023-04-14
CU24093B1 (es) 2015-04-29
CU20150024A7 (es) 2015-09-29
CA3070823C (en) 2021-09-21
AU2010258214B2 (en) 2015-08-20
MX2011013119A (es) 2012-07-04
CN106905232B (zh) 2019-09-27
DK2440546T3 (da) 2023-03-27
WO2010143170A2 (en) 2010-12-16
CA2764027A1 (en) 2010-12-16
ES2736198T3 (es) 2019-12-26
PL2440547T3 (pl) 2023-09-11
CA2764026C (en) 2019-10-29
CU20110229A7 (es) 2012-06-21
BRPI1010772B1 (pt) 2020-10-27
KR20120049860A (ko) 2012-05-17
EP2440547A2 (en) 2012-04-18
KR20190018568A (ko) 2019-02-22
KR101982462B1 (ko) 2019-05-24

Similar Documents

Publication Publication Date Title
BRPI1012892B8 (pt) compostos de fórmula (i), como tal, composição farmacêutica que os compreende e seu uso no tratamento de hgps, progeria, desordem de charcot-marie-tooth, síndrome de werner, diabetes, osteoporose e envelhecimento da pele
BR112012021652A2 (pt) composto, uso do mesmo, e, composição farmacêutica
BR112012027385A2 (pt) composição para o controle de doenças de plantas e uso da mesma
ECSP099330A (es) Compuesto de indol
BR112015000373A2 (pt) metódo para produzir composto de politiol, composição polimerizável para material ótico e usos dos mesmos
BR112014000665B8 (pt) composto, composição farmacêutica, agente antimicrobiano, e, uso de um composto
BR112013006936A2 (pt) composto de amida substituída
PA8848201A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
BR112012021656A2 (pt) composto, uso do mesmo, e, composição farmacêutica
BR112013014943A8 (pt) Compostos da fórmula (i) e composição farmacêutica
BR112012010186B8 (pt) derivados de heteroarila contendo n como inibidores de quinase jak3 e composição farmacêutica compreendendo os mesmos
CR20210520A (es) Inhibidores de dihidroorotato deshidrogenasa
BR112014010628A2 (pt) compostos pesticidas
BR112013001632A2 (pt) composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto
BR112012033465A2 (pt) método para preparar um composto
BR112014010133A8 (pt) compostos pesticidas
AR080969A1 (es) Compuesto biciclico
BR112012027387A2 (pt) composição para controle de doenças de plantas e uso da mesma
CO7160013A2 (es) Derivados de amida cíclica como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa y los usos de los mismos
BR112013024368A8 (pt) Combinações de composto ativo
BR112013017520A2 (pt) composto bicíclico ou sal do mesmo
MX2019008390A (es) Compuestos utiles para tratar cancer.
WO2014047232A3 (en) C-rel inhibitors and uses thereof
BR112015006979A2 (pt) compostos anti-invasivos
BR112021019367A2 (pt) Trans-n-[4-[2-[4-(2,3-diclorofenil)piperazin-1-il]etil]ciclo-hexil]-n?, n?-dimetilureia, uso de trans-n-[4-[2-[4-(2,3-diclorofenil)piperazin-1-il]etil]ciclo-hexil]-n?, n?-dimetilureia, composição farmacêutica, e, método para tratar uma doença ou transtorno

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR)

B25A Requested transfer of rights approved

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR)

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/06/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF